Notice Number: NOT-AG-18-023

Key Dates
Release Date: July 18, 2018

Issued by
National Institute on Aging (NIA)

Purpose

This guide notice is to provide additional clarifying information to applicants interested in applying to the Alzheimer's Clinical Trials Consortium (ACTC). The ACTC is a clinical trials infrastructure designed to accelerate and expand studies for therapies in Alzheimer's disease and related dementias.

The ACTC infrastructure is welcoming of:

• Academic and industry applicants.
• Both pharmacological and non-pharmacological interventions. 

Applications are encouraged that propose:

• Testing candidate therapeutic compounds against novel therapeutic targets.
• Testing repurposed drugs derived from data driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032).

Logistical guidance:

• Prior to applying to the ACTC Funding Opportunity Announcement (PAR-18-513), investigators are strongly encouraged to contact NIA staff and the ACTC study team.
• Potential applicants must undergo initial vetting of proposed application by the ACTC steering committee.
• Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found here.
• Applications should anticipate using a centralized IRB.
• Applicants should be aware of the data and resource sharing requirements.
• The use of common contract language is strongly encouraged.

• Note, the ACTC infrastructure is not appropriate for:
• Single site clinical trials
• Routine Phase I, first-in-human single, or multiple ascending dose studies.

Inquiries

Please direct all inquiries to:

Pharmacological Interventions:

Laurie Ryan, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: [email protected]

Non-Pharmacological Interventions:

Kristina McLinden, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: [email protected]